Existing cell culture models were not very realistic, Tuveson says, and creating genetically engineered mice took up to a year, compared with up to 3 weeks for
pancreatic cancer organoids.
Not exact matches
The
organoids have already helped clarify new pathways that lead to
pancreatic cancer, Tuveson says, and unpublished data suggest that they will help researchers predict which treatments will be most effective.
Once they have grown to a sufficient size, the
organoids can be transplanted back into mice, where they fully recapitulate
pancreatic cancer.
«With this development, we are now able to culture both mouse and human
organoids, providing a very powerful tool in our fight against
pancreatic cancer,» explains Tuveson.
The team used
pancreatic organoid technology developed in the lab of Professor David Tuveson, Director of CSHL's
Cancer Center and Director of Research for the Lustgarten Foundation.
A bid to improve near - zero survival rates for
pancreatic cancer will receive a boost with the creation of Australia's first
pancreatic cancer «
organoids bank», enabling researchers to bring down the time it takes to find individualised chemotherapy treatment within weeks rather than months.
Experiments on pancreas
organoids — models that are essentially balls of cells sampled from the pancreas of healthy people and
pancreatic cancer patients — showed that lowering antioxidant levels within cancerous pancreas cells, or cells on the way to becoming cancerous, kills them.